세계의 RA(Regulatory Affairs) 아웃소싱 시장 규모 - 서비스, 카테고리, 적응증, 제품 단계, 최종 사용자별 - 지역별 전망, 경쟁 전략, 부문 예측(-2033년)

Regulatory Affairs Outsourcing Market Size- By Service, By Category, By Indication, By Product Stage, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033

US $ 4,250 ￦ 5,810,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인용 시에는 출처를 명시해 주시기 바랍니다

US $ 5,650 ￦ 7,724,000

PDF (Group License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄는 5회까지 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 인용 시에는 출처를 명시해 주시기 바랍니다.

US $ 7,450 ￦ 10,184,000

PDF (Company License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 인용 시에는 출처를 명시해 주시기 바랍니다.

한글목차

세계 RA(Regulatory Affairs) 아웃소싱 시장 규모는 2033년까지 10.92%의 연평균 복합 성장률(CAGR)로 20억 9,618만 달러 규모로 성장할 것으로 예상됩니다.

시민의 건강을 보호하기 위해 농약, 화장품, 살충제, 의료기기, 의약품, 동물용 의약품, 보완대체의학 등 다양한 산업 분야의 제품을 조사하고 심사하는 것이 규제 관련 업무입니다. 의약품, 생물의약품, 의료기기, 의료용품을 제조하는 기업들에게 규제 관련 업무를 아웃소싱하는 것이 유리하게 작용할 수 있습니다.

코로나19로 인한 광범위한 봉쇄로 인해 암을 포함한 일부 만성질환에 대한 임상시험이 중단되었습니다. 임상시험의 감소로 인해 의약품 신청 아웃소싱 서비스 시장이 침체되었고, 공급망의 혼란은 의약품의 제조 및 유통에 영향을 미쳐 시장 확대를 크게 저해하고 있습니다.

세계 RA(Regulatory Affairs) 아웃소싱(Regulatory Affairs Outsourcing) 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 시장 규모 추이 및 예측, 각종 부문별/지역별 상세 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 시장 역학

• 성장 촉진요인 및 억제요인, 기회, 과제 분석
• 시장에 대한 COVID-19의 영향

제5장 시장 변수와 전망

• SWOT 분석
• PESTEL 분석
• Porter의 Five Forces 분석
• 히트맵 분석

제6장 경쟁 구도

• 제조거점 분포·판매 지역·제품 유형
• 인수합병(M&A)·제휴·제품 발매·협력

제7장 세계의 RA(Regulatory Affairs) 아웃소싱 시장 : 서비스별

• 세계 시장 규모 점유율·예측
• 규제 컨설팅
  • 전략과 개발 계획
  • QA컨설팅
  • 기타
• 법적 대리
• 규제 문서 집필 및 출판
• 제품 등록 및 임상시험 신청
• 약사 업무
• 규제기관 제출
• 기타

제8장 세계의 RA(Regulatory Affairs) 아웃소싱 시장 : 카테고리별

• 세계 시장 규모 점유율·예측
• 의약품
  • 규제 컨설팅
  • 법적 대리
  • 규제 문서 집필 및 출판
  • 제품 등록 및 임상시험 신청
  • 약사 신청
  • 약사 업무
  • 기타
• 의료기기
  • 규제 컨설팅
  • 법적 대리
  • 규제 문서 집필 및 출판
  • 제품 등록 및 임상시험 신청
  • 약사 신청
  • 약사 업무
• 기타

제9장 세계의 RA(Regulatory Affairs) 아웃소싱 시장 : 적응증별

• 세계 시장 규모 점유율·예측
• 종양
• 신경
• 심장병
• 면역
• 기타

제10장 세계의 RA(Regulatory Affairs) 아웃소싱 시장 : 제품 스테이지별

• 세계 시장 규모 점유율·예측
• 전임상
• 임상
• PMA(시판 후 승인)

제11장 세계의 RA(Regulatory Affairs) 아웃소싱 시장 : 최종사용자별

• 세계 시장 규모 점유율·예측
• 의료기기 기업
• 제약회사
• 바이오테크놀러지 기업
• 기타

제12장 세계의 RA(Regulatory Affairs) 아웃소싱 시장 예측

• 시장 규모·시장 점유율

제13장 세계의 RA(Regulatory Affairs) 아웃소싱 시장 : 서비스별

• 시장 규모·시장 점유율 추이·예측

제14장 세계의 RA(Regulatory Affairs) 아웃소싱 시장 : 카테고리별

• 시장 규모·시장 점유율 추이·예측

제15장 세계의 RA(Regulatory Affairs) 아웃소싱 시장 : 적응증별

• 시장 규모·시장 점유율 추이·예측

제16장 세계의 RA(Regulatory Affairs) 아웃소싱 시장 : 제품 단계별

• 시장 규모·시장 점유율 추이·예측

제17장 세계의 RA(Regulatory Affairs) 아웃소싱 시장 : 최종사용자별

• 시장 규모·시장 점유율 추이·예측

제18장 세계의 RA(Regulatory Affairs) 아웃소싱 시장 : 지역별

• 시장 규모·시장 점유율 추이·예측
• 아시아태평양
• 유럽
• 중동 및 아프리카
• 북미
• 라틴아메리카

제19장 기업 개요

• Accell Clinical Research, LLC
• Genpact
• CRITERIUM, INC
• Promedica International
• WuXi AppTec
• Medpace
• Charles River Laboratories
• ICON plc
• Labcorp Drug Development
• Parexel International Corporation
• Freyr
• PHARMALEX GMBH
• NDA Group AB
• Pharmexon
• Qvigilance
• BlueReg
• Cambridge Regulatory Services
• APCER Life Sciences, Inc.
• Real Regulatory Ltd
• VCLS
• PrimeVigilance
• ProPharma Group MIS Limited
• 기타

제20장 약어 리스트

제21장 참고 링크

제22장 결론

제23장 조사 범위

LSH

영문 목차

영문목차

Regulatory Affairs Outsourcing Market Introduction and Overview

According to SPER market research, 'Regulatory Affairs Outsourcing Market Size- By Service, By Category, By Indication, By Product Stage, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033' state that the Regulatory Affairs Outsourcing Market is predicted to reach 20896.18 million by 2033 with a CAGR of 10.92%.

In order to safeguard the general public's health, government affairs, also known as regulatory affairs, is the study and examination of goods from a variety of industries, including agrochemicals, cosmetics, pesticides, medical devices, pharmaceuticals, veterinary medications, and complementary and alternative medicine. Outsourcing regulatory issues may be advantageous for companies that produce pharmaceuticals, biomedical equipment, and medical supplies.

The pandemic's widespread lockdowns caused by the high number of COVID-19 cases it included disrupted clinical trials for several chronic diseases, including cancer. The pandemic's reduction in clinical study numbers resulted in a downturn in the market for healthcare regulatory affairs outsourcing services. As a result, early pandemic disruptions in the global supply chain affected pharmaceutical product manufacturing and distribution, which significantly hindered market expansion.

Scope of the Report:

Report Metric Details

Market size available for years 2020-2033

Base year considered 2023

Forecast period 2024-2033

Segments covered By Service, By Category, By Indication, By Product Stage, By End User

Regions covered North America, Asia-Pacific, Latin America, Middle East & Africa and Europe

Companies Covered Accell Clinical Research, LLC, Genpact, CRITERIUM, INC, Promedica International, WuXi AppTec, Medpace, Charles River Laboratories, Pharmexon, Qvigilance, BlueReg, Cambridge Regulatory Services, APCER Life Sciences, Inc, Real Regulatory Ltd, ProPharma Group MIS Limited.

Regulatory Affairs Outsourcing Market Segmentation

By Service: Based on the Service, Global Regulatory Affairs Outsourcing Market is segmented as; Regulatory Consulting, Legal Representation, Regulatory Writing & Publishing, Product Registration & Clinical Trial Applications, Regulatory Operations, Regulatory Submissions, Others.

By Category: Based on the Category, Global Regulatory Affairs Outsourcing Market is segmented as; Pharmaceuticals, Medical Device, Others.

By Indication: Based on the Indication, Global Regulatory Affairs Outsourcing Market is segmented as; Oncology, Neurology, Cardiology, Immunology, Others.

By Product Stage: Based on the Product Stage, Global Regulatory Affairs Outsourcing Market is segmented as; Preclinical, Clinical, PMA, Others.

Table of Contents

1. Introduction

• 1.1. Scope of the report
• 1.2. Market segment analysis

2. Research Methodology

• 2.1. Research data source
  • 2.1.1. Secondary Data
  • 2.1.2. Primary Data
  • 2.1.3. SPER's internal database
  • 2.1.4. Premium insight from KOL's
• 2.2. Market size estimation
  • 2.2.1. Top-down and Bottom-up approach
• 2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

• 4.1. Driver, Restraint, Opportunity and Challenges analysis
  • 4.1.1. Drivers
  • 4.1.2. Restraints
  • 4.1.3. Opportunities
  • 4.1.4. Challenges
• 4.2. COVID-19 Impacts of the Global Regulatory Affairs Outsourcing Market

5. Market variable and outlook

• 5.1. SWOT Analysis
  • 5.1.1. Strengths
  • 5.1.2. Weaknesses
  • 5.1.3. Opportunities
  • 5.1.4. Threats
• 5.2. PESTEL Analysis
  • 5.2.1. Political Landscape
  • 5.2.2. Economic Landscape
  • 5.2.3. Social Landscape
  • 5.2.4. Technological Landscape
  • 5.2.5. Environmental Landscape
  • 5.2.6. Legal Landscape
• 5.3. PORTER's Five Forces
  • 5.3.1. Bargaining power of suppliers
  • 5.3.2. Bargaining power of buyers
  • 5.3.3. Threat of Substitute
  • 5.3.4. Threat of new entrant
  • 5.3.5. Competitive rivalry
• 5.4. Heat Map Analysis

6. Competitive Landscape

• 6.1. Global Regulatory Affairs Outsourcing Market Manufacturing Base Distribution, Sales Area, Ingredients
• 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Regulatory Affairs Outsourcing Market

7. Global Regulatory Affairs Outsourcing Market, By Service (USD Million)

• 7.1. Global Regulatory Affairs Outsourcing Market Value Share and Forecast, By Service 2024-2033
• 7.2. Regulatory Consulting
  • 7.2.1. Strategy & Development Planning
  • 7.2.2. QA Consulting
  • 7.2.3. Others
• 7.3. Legal Representation
• 7.4. Regulatory Writing & Publishing
• 7.5. Product Registration & Clinical Trial Applications
• 7.6. Regulatory Operations
• 7.7. Regulatory Submission
• 7.8. Others

8. Global Regulatory Affairs Outsourcing Market, By Category (USD Million)

• 8.1. Global Regulatory Affairs Outsourcing Market Value Share and Forecast, By Category 2024-2033
• 8.2. Pharmaceuticals
  • 8.2.1. Regulatory Consulting
  • 8.2.2. Legal Representation
  • 8.2.3. Regulatory Writing & Publishing
  • 8.2.4. Product Registration & Clinical Trial Applications
  • 8.2.5. Regulatory Submissions
  • 8.2.6. Regulatory Operations
  • 8.2.7. Others
• 8.3. Medical Device
  • 8.3.1. Regulatory Consulting
  • 8.3.2. Legal Representation
  • 8.3.3. Regulatory Writing & Publishing
  • 8.3.4. Product Registration & Clinical Trial Applications
  • 8.3.5. Regulatory Submissions
  • 8.3.6. Regulatory Operations
• 8.4. Others

9. Global Regulatory Affairs Outsourcing Market, By Indication (USD Million)

• 9.1. Global Regulatory Affairs Outsourcing Market Size Value Share and Forecast, By Indication 2024-2033
• 9.2. Oncology
• 9.3. Neurology
• 9.4. Cardiology
• 9.5. Immunology
• 9.6. Others

10. Global Regulatory Affairs Outsourcing Market, By Product Stage (USD Million)

• 10.1. Global Regulatory Affairs Outsourcing Market Size Value Share and Forecast, By Product Stage 2024-2033
• 10.2. Preclinical
• 10.3. Clinical
• 10.4. PMA (Post Market Authorization

11. Global Regulatory Affairs Outsourcing Market, By End User (USD Million)

• 11.1. Global Regulatory Affairs Outsourcing Market Size Value Share and Forecast, By End User 2024-2033
• 11.2. Medical Device Companies
• 11.3. Pharmaceutical Companies
• 11.4. Biotechnology Companies
• 11.5. Others

12. Global Regulatory Affairs Outsourcing Market, Forecast, 2020-2033 (USD Million)

• 12.1. Global Regulatory Affairs Outsourcing Market Size and Market Share

13. Global Regulatory Affairs Outsourcing Market, By Service 2020-2033 (USD Million)

• 13.1. Global Regulatory Affairs Outsourcing Market Size and Market Share, By Service (2020-2026)
• 13.2. Global Regulatory Affairs Outsourcing Market Size and Market Share, By Service (2027-2033)

14. Global Regulatory Affairs Outsourcing Market, By Category 2020-2033 (USD Million)

• 14.1. Global Regulatory Affairs Outsourcing Market Size and Market Share, By Category (2020-2026)
• 14.2. Global Regulatory Affairs Outsourcing Market Size and Market Share, By Category (2027-2033)

15. Global Regulatory Affairs Outsourcing Market, By Indication 2020-2033 (USD Million)

• 15.1. Global Regulatory Affairs Outsourcing Market Size and Market Share, By Indication (2020-2026)
• 15.2. Global Regulatory Affairs Outsourcing Market Size and Market Share, By Indication (2027-2033)

16. Global Regulatory Affairs Outsourcing Market, By Product Stage 2020-2033 (USD Million)

• 16.1. Global Regulatory Affairs Outsourcing Market Size and Market Share, By Product Stage (2020-2026)
• 16.2. Global Regulatory Affairs Outsourcing Market Size and Market Share, By Product Stage (2027-2033)

17. Global Regulatory Affairs Outsourcing Market, By End User 2020-2033 (USD Million)

• 17.1. Global Regulatory Affairs Outsourcing Market Size and Market Share, By End User (2020-2026)
• 17.2. Global Regulatory Affairs Outsourcing Market Size and Market Share, By End User (2027-2033)

18. Global Regulatory Affairs Outsourcing Market, By Region, 2020-2033 (USD Million)

• 18.1. Global Regulatory Affairs Outsourcing Market Size and Market Share, By Region (2020-2026)
• 18.2. Global Regulatory Affairs Outsourcing Market Size and Market Share, By Region (2027-2033)
• 18.3. Asia-Pacific
  • 18.3.1. Australia
  • 18.3.2. China
  • 18.3.3. India
  • 18.3.4. Japan
  • 18.3.5. South Korea
  • 18.3.6. Rest of Asia-Pacific
• 18.4. Europe
  • 18.4.1. France
  • 18.4.2. Germany
  • 18.4.3. Italy
  • 18.4.4. Spain
  • 18.4.5. United Kingdom
  • 18.4.6. Rest of Europe
• 18.5. Middle East and Africa
  • 18.5.1. Kingdom of Saudi Arabia
  • 18.5.2. United Arab Emirates
  • 18.5.3. Rest of Middle East & Africa
• 18.6. North America
  • 18.6.1. Canada
  • 18.6.2. Mexico
  • 18.6.3. United States
• 18.7. Latin America
  • 18.7.1. Argentina
  • 18.7.2. Brazil
  • 18.7.3. Rest of Latin America

19. Company Profile

• 19.1. Accell Clinical Research, LLC
  • 19.1.1. Company details
  • 19.1.2. Financial outlook
  • 19.1.3. Product summary
  • 19.1.4. Recent developments
• 19.2. Genpact
  • 19.2.1. Company details
  • 19.2.2. Financial outlook
  • 19.2.3. Product summary
  • 19.2.4. Recent developments
• 19.3. CRITERIUM, INC
  • 19.3.1. Company details
  • 19.3.2. Financial outlook
  • 19.3.3. Product summary
  • 19.3.4. Recent developments
• 19.4. Promedica International
  • 19.4.1. Company details
  • 19.4.2. Financial outlook
  • 19.4.3. Product summary
  • 19.4.4. Recent developments
• 19.5. WuXi AppTec
  • 19.5.1. Company details
  • 19.5.2. Financial outlook
  • 19.5.3. Product summary
  • 19.5.4. Recent developments
• 19.6. Medpace
  • 19.6.1. Company details
  • 19.6.2. Financial outlook
  • 19.6.3. Product summary
  • 19.6.4. Recent developments
• 19.7. Charles River Laboratories
  • 19.7.1. Company details
  • 19.7.2. Financial outlook
  • 19.7.3. Product summary
  • 19.7.4. Recent developments
• 19.8. ICON plc
  • 19.8.1. Company details
  • 19.8.2. Financial outlook
  • 19.8.3. Product summary
  • 19.8.4. Recent developments
• 19.9. Labcorp Drug Development
  • 19.9.1. Company details
  • 19.9.2. Financial outlook
  • 19.9.3. Product summary
  • 19.9.4. Recent developments
• 19.10. Parexel International Corporation
  • 19.10.1. Company details
  • 19.10.2. Financial outlook
  • 19.10.3. Product summary
  • 19.10.4. Recent developments
• 19.11. Freyr
  • 19.11.1. Company details
  • 19.11.2. Financial outlook
  • 19.11.3. Product summary
  • 19.11.4. Recent developments
• 19.12. PHARMALEX GMBH
  • 19.12.1. Company details
  • 19.12.2. Financial outlook
  • 19.12.3. Product summary
  • 19.12.4. Recent developments
• 19.13. NDA Group AB
  • 19.13.1. Company details
  • 19.13.2. Financial outlook
  • 19.13.3. Product summary
  • 19.13.4. Recent developments
• 19.14. Pharmexon
  • 19.14.1. Company details
  • 19.14.2. Financial outlook
  • 19.14.3. Product summary
  • 19.14.4. Recent developments
• 19.15. Qvigilance
  • 19.15.1. Company details
  • 19.15.2. Financial outlook
  • 19.15.3. Product summary
  • 19.15.4. Recent developments
• 19.16. BlueReg
  • 19.16.1. Company details
  • 19.16.2. Financial outlook
  • 19.16.3. Product summary
  • 19.16.4. Recent developments
• 19.17. Cambridge Regulatory Services
  • 19.17.1. Company details
  • 19.17.2. Financial outlook
  • 19.17.3. Product summary
  • 19.17.4. Recent developments
• 19.18. APCER Life Sciences, Inc.
  • 19.18.1. Company details
  • 19.18.2. Financial outlook
  • 19.18.3. Product summary
  • 19.18.4. Recent developments
• 19.19. Real Regulatory Ltd
  • 19.19.1. Company details
  • 19.19.2. Financial outlook
  • 19.19.3. Product summary
  • 19.19.4. Recent developments
• 19.20. VCLS
  • 19.20.1. Company details
  • 19.20.2. Financial outlook
  • 19.20.3. Product summary
  • 19.20.4. Recent developments
• 19.21. PrimeVigilance
  • 19.21.1. Company details
  • 19.21.2. Financial outlook
  • 19.21.3. Product summary
  • 19.21.4. Recent developments
• 19.22. ProPharma Group MIS Limited
  • 19.22.1. Company details
  • 19.22.2. Financial outlook
  • 19.22.3. Product summary
  • 19.22.4. Recent developments
• 19.23. Others

20. List of Abbreviations

21. Reference Links

22. Conclusion

23. Research Scope

관련자료